comparemela.com

Latest Breaking News On - பிளாட்டிரான் ஆரோக்கியம் - Page 13 : comparemela.com

Pharmaceutical and Life Sciences Real World Evidence Market Outlook 2021-2030: Comparison of Randomized Clinical Trials and Real World Evidence

Pharmaceutical and Life Sciences Real World Evidence Market Outlook 2021-2030: Comparison of Randomized Clinical Trials and Real World Evidence
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Ask HN: Who is hiring? (May 2021)

Citrine Informatics | Sr. Backend Engineer, SRE, Sr. Frontend Engineer | Full-time | Headquartered in Redwood City, CA but REMOTE EMPLOYEES WELCOME TO APPLY | https://citrine.io/ Citrine Informatics is a fast growing late Series B B2B Saas startup. Our mission is to empower companies to make raw materials and chemicals faster and with sustainability top of mind. As an Engineer at Citrine you ll help design and build Citrine’s scalable smart data infrastructure and AI platform powering development and discovery of next-generation materials and chemicals. Our Stack: Scala, Python, Java, React/Redux, MySQL, AWS, Elasticsearch, Redis, Swagger, Typescript Tests/Design Please check out our careers page to learn more and apply https://citrine.io/careers/.

Turner Novak is monetizing memes with venture capital

Turner Novak is monetizing memes with venture capital Banana Capital is an early-stage VC firm managing ~$10m. A key part of the fund s investing strategy: creating memes to get mindshare and win over both founders and other investors. By: Trung T. Phan | @TrungTPhan April 29, 2021 If you’ve been anywhere near tech Twitter over the past year, you’ve seen a viral tweet from Turner Novak.  The 30-year old investor pumps out investment memes and conjures up hysterical parodies of tech founding stories (seriously, read these and try not to laugh). “Founding stories” for It’s a very deliberate approach with an end goal in mind.

Ophelia Raises $15m in Series A Funding

Ophelia, a NYC-based healthcare tech startup providing treatment for Opioid Use Disorder (OUD), raised $15m in Series A funding. The round was led by Menlo Ventures with participation from Y Combinator, General Catalyst, Refactor Capital, and the founders of Flatiron Health, Warby Parker, Harry’s, Allbirds, PillPack, Carbon Health, and Lambda School. The company intends to use the funds to continue to build and expand its services to patients across the U.S., to soon accept insurance, including Medicare and Medicaid. Led by Zack Gray, Co-founder and CEO, Ophelia offers an alternative to traditional rehab for the treatment of OUD. Through its telemedicine platform, the company provides Medication-Assisted Treatment (MAT) in a private way for patients who otherwise have no way to access care. MAT works through a combination of medication to stop opioid withdrawal and cravings, plus support and therapy for patients when helpful.

Immunotherapy alone extended life for certain metastatic lung cancer patients

Immunotherapy alone extended life for certain metastatic lung cancer patients Real-world evidence is suggesting, for the first time, the most beneficial treatment courses that could help extend the lives of patients with metastatic non-small cell lung cancer, according to research from the Abramson Cancer Center. In a new study published online in JAMA Oncology, researchers show that patients harboring a KRAS gene mutation with high levels of PDL-1 lived longer when treated with immunotherapy alone, compared to patients without this mutation. This survival difference by KRAS status was not seen, however, in patients treated with both chemotherapy and immunotherapy, suggesting combination therapy for patients without the mutation may be preferred.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.